Shadli, Shabah M. http://orcid.org/0000-0002-3607-3469
Ando, Lynne C.
McIntosh, Julia
Lodhia, Veema http://orcid.org/0000-0002-3205-9811
Russell, Bruce R. http://orcid.org/0000-0001-6935-1974
Kirk, Ian J. http://orcid.org/0000-0002-0444-6718
Glue, Paul http://orcid.org/0000-0002-7305-2800
McNaughton, Neil http://orcid.org/0000-0003-4348-8221
Funding for this research was provided by:
Health Research Council of New Zealand (14/129, 19/027)
Article History
Received: 17 February 2021
Accepted: 23 September 2021
First Online: 5 October 2021
Competing interests
: PG has a contract with Douglas Pharmaceuticals to develop novel ketamine formulations. Within the last 3 years, PG has participated in an advisory board for Janssen Pharma and NMcN has had a confidential consulting agreement with Janssen Research & Development, LLC. No other authors have any conflicts to declare.